+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "JAK Inhibitor"

JAK Inhibitors Market - Product Thumbnail Image

JAK Inhibitors Market

  • Report
  • May 2024
  • 200 Pages
  • Global
From
Androgenetic Alopecia Market - Product Thumbnail Image

Androgenetic Alopecia Market

  • Report
  • March 2024
  • 200 Pages
  • Global
From
Tofacitinib Global Market Opportunities and Strategies to 2032 - Product Thumbnail Image

Tofacitinib Global Market Opportunities and Strategies to 2032

  • Report
  • January 2024
  • 244 Pages
  • Global
From
From
Alopecia Market Analysis & Forecast to 2024-2034 - Product Thumbnail Image

Alopecia Market Analysis & Forecast to 2024-2034

  • Report
  • May 2024
  • 200 Pages
  • Global
From
Graft Versus Host Disease (GvHD) Treatment Market - Product Thumbnail Image

Graft Versus Host Disease (GvHD) Treatment Market

  • Report
  • March 2024
  • 200 Pages
  • Global
From
From
From
Alopecia Areata- Pipeline Insight, 2025 - Product Thumbnail Image

Alopecia Areata- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Loading Indicator

The JAK Inhibitor market is a subset of the larger Immune Disorders Drugs market. JAK Inhibitors are a type of drug used to treat a variety of immune-related disorders, such as rheumatoid arthritis, psoriasis, and Crohn's disease. These drugs work by blocking the activity of Janus kinase (JAK) enzymes, which are involved in the body's inflammatory response. JAK Inhibitors are typically taken orally, and are often used in combination with other medications. The JAK Inhibitor market is highly competitive, with a number of large pharmaceutical companies vying for market share. Some of the major players in the market include AbbVie, Pfizer, Novartis, and Johnson & Johnson. Other companies, such as Celgene, Merck, and Eli Lilly, are also active in the market. Show Less Read more